JPWO2020238998A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020238998A5 JPWO2020238998A5 JP2021569941A JP2021569941A JPWO2020238998A5 JP WO2020238998 A5 JPWO2020238998 A5 JP WO2020238998A5 JP 2021569941 A JP2021569941 A JP 2021569941A JP 2021569941 A JP2021569941 A JP 2021569941A JP WO2020238998 A5 JPWO2020238998 A5 JP WO2020238998A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- set forth
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 29
- 108090001123 antibodies Proteins 0.000 claims 29
- 101700073818 CDR1 Proteins 0.000 claims 17
- 102100002977 CDR1 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 108060001277 CDR2 Proteins 0.000 claims 16
- 101700027814 CDR3 Proteins 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 9
- 102000038129 antigens Human genes 0.000 claims 9
- 108091007172 antigens Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 101700043017 NTRK1 Proteins 0.000 claims 4
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 102220396879 ADAL F16P Human genes 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 210000000013 Bile Ducts Anatomy 0.000 claims 1
- 102200080226 CARD19 L17A Human genes 0.000 claims 1
- 206010058019 Cancer pain Diseases 0.000 claims 1
- 210000002808 Connective Tissue Anatomy 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 210000001117 Keloid Anatomy 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- 206010028537 Myelofibrosis Diseases 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000003476 Primary Myelofibrosis Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 101710004265 RPL23 Proteins 0.000 claims 1
- 208000003782 Raynaud Disease Diseases 0.000 claims 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 230000001746 atrial Effects 0.000 claims 1
- 102220350425 c.28T>C Human genes 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 230000026749 regulation of bone remodeling Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910464016.0 | 2019-05-30 | ||
| CN201910464016 | 2019-05-30 | ||
| PCT/CN2020/092766 WO2020238998A1 (en) | 2019-05-30 | 2020-05-28 | Anti-trka antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533855A JP2022533855A (ja) | 2022-07-26 |
| JPWO2020238998A5 true JPWO2020238998A5 (zh) | 2022-08-02 |
Family
ID=73506735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569941A Pending JP2022533855A (ja) | 2019-05-30 | 2020-05-28 | 抗ＴｒｋＡ抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220204630A1 (zh) |
| EP (1) | EP3976657A4 (zh) |
| JP (1) | JP2022533855A (zh) |
| CN (2) | CN114230663B (zh) |
| AU (1) | AU2020281378A1 (zh) |
| TW (1) | TW202110888A (zh) |
| WO (1) | WO2020238998A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023549300A (ja) * | 2020-11-20 | 2023-11-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ヒト化抗ＴｒｋＡ抗体及びその使用 |
| CN117264068A (zh) * | 2021-02-28 | 2023-12-22 | 熙源安健医药（上海）有限公司 | 抗TrkA抗体或其抗原结合片段、其制备方法和应用 |
| WO2023125477A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkA ANTIBODY AND APPLICATION THEREOF |
| CN115611985A (zh) * | 2022-10-27 | 2023-01-17 | 合肥天港免疫药物有限公司 | 抗cd3的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0326780D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| US8911726B2 (en) * | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| DK2252633T3 (da) * | 2008-02-04 | 2013-11-11 | Lay Line Genomics Spa | Anti-TrkA antistoffer og derivater deraf |
| US8183346B2 (en) * | 2008-12-05 | 2012-05-22 | Eli Lilly And Company | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
| DK2766392T3 (da) * | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
| JP2015520182A (ja) * | 2012-06-08 | 2015-07-16 | グレンマーク ファーマシューティカルズ， エセ．アー． | アミノ酸置換を有するヒト化抗ＴｒｋＡ抗体 |
| EP2674439B1 (en) * | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| US20190184015A1 (en) * | 2016-09-02 | 2019-06-20 | European Molecular Biology Laboratory | Irradiation treatment of neurological sensations by photoablation |
| EP3596130A4 (en) * | 2017-03-14 | 2020-12-30 | Sunshine Lake Pharma Co., Ltd. | DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN |
-
2020
- 2020-05-28 CN CN202111390356.7A patent/CN114230663B/zh active Active
- 2020-05-28 WO PCT/CN2020/092766 patent/WO2020238998A1/en unknown
- 2020-05-28 JP JP2021569941A patent/JP2022533855A/ja active Pending
- 2020-05-28 US US17/604,728 patent/US20220204630A1/en active Pending
- 2020-05-28 AU AU2020281378A patent/AU2020281378A1/en active Pending
- 2020-05-28 EP EP20814249.7A patent/EP3976657A4/en active Pending
- 2020-05-28 CN CN202010465851.9A patent/CN112010978B/zh active Active
- 2020-05-29 TW TW109118203A patent/TW202110888A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304375B2 (ja) | 血清アルブミンに結合するタンパク質 | |
| JP7417421B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| US20230060574A1 (en) | Serum albumin binders | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP6779252B2 (ja) | ＩＬ−１βへの結合メンバー | |
| EP2934584B1 (en) | Anti-gdf15 antibodies | |
| US10703813B2 (en) | Anti IL-34 antibodies | |
| JP2020506898A (ja) | 改善された血清アルブミン結合剤 | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| US11780916B2 (en) | GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof | |
| TWI734410B (zh) | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 | |
| JP2019505565A5 (zh) | ||
| CN110402254B (zh) | 针对fgfr1的单克隆抗体 | |
| JPWO2020238998A5 (zh) | ||
| JP2019509714A5 (zh) | ||
| CN113444176B (zh) | Ngf的抗体及其应用 | |
| CN102863533A (zh) | 抗体人源化改造方法 | |
| KR20220119393A (ko) | 약학 조성물, 이의 제조 방법 및 이의 용도 | |
| RU2800370C2 (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение | |
| WO2018095932A1 (en) | Monoclonal antibody directed to fgfr1 | |
| CN114516917B (zh) | 人源化抗TrkA的抗体及其应用 | |
| TW202233683A (zh) | 針對wnt受體ryk之抗體變異體 |